Thursday 7 May, 2026
Objectives: [¹⁷⁷Lu]Lu-PSMA-617 is an approved radioligand therapy that prolongs survival in metastatic castration-resistant prostate cancer (PCa). The PROQURE‑I trial investigated…
Read morePoster: Drug/Disease Modelling - Oncology
Impact of the use of different PK/PD indexes on amikacin dosing requirements in severely ill children: a population PK approach
Thursday 7 May, 2026
Introduction: Amikacin is a critical antibiotic for treating severe infections in immunocompromised children. Pediatric patients are particularly vulnerable due to…
Read morePopulation PK/PD analysis of roginolisib in healthy participants using the basophil activation test to determine the PI3Kδ occupancy.
Thursday 7 May, 2026
Introduction and Objectives: The highly selective, oral allosteric modulator of PI3Kδ, roginolisib (IOA-244), blocks the activity of PI3Kδ-dependent signalling, in…
Read moreModel-based assessment of isatuximab monthly dosing regimen in relapsed/refractory multiple myeloma patients using IKEMA phase 3 data
Thursday 7 May, 2026
Objectives: Carfilzomib and dexamethasone (Kd) is an effective treatment option for patients with relapsed/refractory multiple myeloma (RRMM). The addition of…
Read morePOPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TECLISTAMAB IN COMBINATION WITH DARATUMUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR LINE OF THERAPY.
Thursday 7 May, 2026
Objectives: Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), is approved as monotherapy…
Read moreIMMORTAL TIME BIAS IN USING IMMUNE-MEDIATED ADVERSE EVENTS AS PREDICTORS OF SURVIVAL: INSIGHTS FROM A MULTISTATE MODELING APPROACH
Thursday 7 May, 2026
Objectives: Immune-mediated adverse events (IMAE) have been suggested as prognostic factors for progression-free survival (PFS) and overall survival (OS) in…
Read moreINFLUENCE OF NON-ADHERENCE ON THE ESTIMATION OF PHARMACOKINETIC PARAMETERS OF CABOZANTINIB IN RENAL CELL CARCINOMA
Thursday 7 May, 2026
INTRODUCTION Oral anticancer drugs (OADs) play a vital role in modern cancer therapy. However, they require a high degree of…
Read moreQUANTITATIVE SYSTEMS PHARMACOLOGY GUIDED MABEL ESTIMATION FOR T-CELL ENGAGERS (TCE): A CASE STUDY TO SUPPORT MODEL-INFORMED FIRST-IN-HUMAN DOSE SELECTION
Thursday 7 May, 2026
OBJECTIVES CD3 T-cell engagers (TCEs) pose a significant risk of cytokine release syndrome (CRS), making accurate first-in-human (FIH) dose selection…
Read moreCancer-Driven Changes in Small Intestinal and Colonic Drug-Metabolising Enzymes and Transporters: Updating Cancer Populations for PBPK Modelling and Pharmacokinetic Implications
Thursday 7 May, 2026
Objectives Small intestine cancer is rare, with a steady rise over the last decades. Because of its rarity, clinical trials…
Read moreFROM CAPILLARY TO CLINIC: MODEL-BASED TRANSLATION OF VOLUMETRIC ABSORPTIVE MICROSAMPLING CONCENTRATIONS FOR THERAPEUTIC DRUG MONITORING OF CABOZANTINIB
Thursday 7 May, 2026
Objective:Substantial interindividual pharmacokinetic variability results in up to 45% of patients receiving oral anticancer drugs being under- or overexposed[1]. Therapeutic…
Read more